AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca total liabilities ($M) ($M)
Consolidated Statement of Financial Position (Postgres DB)
Latest, Q2 2026
65,463
Period ended Jun 30, 2026
Change on a year earlier
-3.2%
67,612 in Q2 2025
History
21 quarters
Since Q4 2015
Sources
18
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total liabilities ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 65,463 | -3.2% | Form 6-K (filed 2026-07-27) ↗ |
| Q4 2025 | Dec 31, 2025 | 65,355 | +3.5% | Form 20-F (filed 2026-02-24) ↗ |
| Q2 2025 | Jun 30, 2025 | 67,612 | +4.4% | Form 6-K (filed 2025-07-29) ↗ |
| Q4 2024 | Dec 31, 2024 | 63,164 | +2.0% | Form 20-F (filed 2025-02-18) ↗ |
| Q2 2024 | Jun 30, 2024 | 64,742 | +9.5% | Form 6-K (filed 2024-07-25) ↗ |
| Q4 2023 | Dec 31, 2023 | 61,953 | +4.3% | Form 20-F (filed 2024-02-20) ↗ |
| Q2 2023 | Jun 30, 2023 | 59,127 | -2.5% | Form 6-K (filed 2023-07-28) ↗ |
| Q4 2022 | Dec 31, 2022 | 59,425 | -10.1% | Form 20-F (filed 2023-02-21) ↗ |
| Q2 2022 | Jun 30, 2022 | 60,628 | +4.6% | Form 6-K (filed 2022-07-29) ↗ |
| Q4 2021 | Dec 31, 2021 | 66,076 | +29.3% | Form 20-F (filed 2022-02-22) ↗ |
| Q2 2021 | Jun 30, 2021 | 57,948 | +25.2% | Form 6-K (filed 2021-07-30) ↗ |
| Q4 2020 | Dec 31, 2020 | 51,091 | +9.2% | Form 20-F (filed 2021-02-16) ↗ |
| Q2 2020 | Jun 30, 2020 | 46,271 | -1.2% | Form 6-K/A (filed 2020-07-31) ↗ |
| Q4 2019 | Dec 31, 2019 | 46,781 | +0.4% | Form 20-F (filed 2020-03-03) ↗ |
| Q2 2019 | Jun 30, 2019 | 46,818 | -0.5% | Form 6-K (filed 2019-07-25) ↗ |
| Q4 2018 | Dec 31, 2018 | 46,607 | -0.2% | Form 20-F (filed 2019-03-05) ↗ |
| Q2 2018 | Jun 30, 2018 | 47,072 | -5.3% | Form 6-K (filed 2018-07-26) ↗ |
| Q4 2017 | Dec 31, 2017 | 46,712 | +1.9% | Form 20-F (filed 2018-03-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 49,707 | – | Form 6-K (filed 2018-07-26) ↗ |
| Q4 2016 | Dec 31, 2016 | 45,857 | +10.4% | Form 20-F (filed 2018-03-06) ↗ |
| Q4 2015 | Dec 31, 2015 | 41,547 | – | Form 20-F (filed 2018-03-06) ↗ |
Breakdown
What makes up total liabilities ($m)
- Total current liabilities ($M)31,553 · Q2 2026
- Trade and other payables — current ($M)22,893 · Q2 2026
- Interest-bearing loans and borrowings — current ($M)5,808 · Q2 2026
- Interest-bearing loans and borrowings — non-current ($M)23,683 · Q2 2026
- Total debt including lease liabilities ($M)-32,239 · Q2 2026
- Deferred tax liabilities ($M)3,463 · Q2 2026
Cite this data
StockData. (2026). AstraZeneca Total liabilities ($M) ($M), quarterly Q4 2015–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/fin_liab
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.